Here’s what we’re looking out for this week in the worlds of pharma and biotech:
Ding, ding, ding! Nasdaq’s biotech index gets a makeover
It’s that time of year: Starting Monday, more than 20 biotech firms will snag a spot on the Nasdaq index — and nearly 40 others will get booted. Among the new arrivals: NantHealth, Aimmune Therapeutics, Editas and Intellia. No longer in favor: OvaScience, MannKind, Flex Pharma, and uniQure, among others. See the complete list here.